| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABT | Common shares without par value | Sale | -$3.02M | -27.7K | -0.4% | $108.77 | 6.95M | 26 Jul 2022 | Direct | F1 |
| transaction | ABT | Common shares without par value | Sale | -$2.44M | -22.3K | -0.32% | $109.60 | 6.92M | 26 Jul 2022 | Direct | F2 |
| holding | ABT | Common shares without par value | 258 | 26 Jul 2022 | Alynne Starks 2012 Irrevocable Trust | F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.32 to $109.31, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.33 to $109.85 inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F3 | Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust. |
These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).